Tags

Type your tag names separated by a space and hit enter

Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach.
Clin Biochem. 2011 Apr; 44(5-6):377-85.CB

Abstract

OBJECTIVES

Parkinson's disease (PD) ranks the second among the neurodegenerative disorders. Proteins involved in Parkinson's disease (PD) have been investigated but none as the diagnostic markers in blood.

DESIGN AND METHODS

In this study, we applied a proteomic strategy, by utilizing two-dimensional electrophoresis and mass spectrometry, to analyze two sample pools of plasma from the healthy individuals and PD subjects.

RESULTS

IgGκL and human serum amyloid P component (SAP) were found differentially expressed between these pools. SAP level increased by approximately 5-fold in PD samples, and the ELISA procedure revealed a significant (P<0.001) increase in SAP concentration (65.9 ± 18.7μg/mL) in the plasma of PD subjects (healthy individuals, 35.0 ± 12.5μg/mL), with sensitivity of 94.1% and specificity of 87.5%.

CONCLUSION

Our results indicated a potential feasibility of plasma SAP as a marker to approach PD.

Authors+Show Affiliations

Graduate Institute of Applied Science and Engineering, Fu-Jen Catholic University, New Taipei City, Taiwan.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21223953

Citation

Chen, Han-Min, et al. "Amyloid P Component as a Plasma Marker for Parkinson's Disease Identified By a Proteomic Approach." Clinical Biochemistry, vol. 44, no. 5-6, 2011, pp. 377-85.
Chen HM, Lin CY, Wang V. Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach. Clin Biochem. 2011;44(5-6):377-85.
Chen, H. M., Lin, C. Y., & Wang, V. (2011). Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach. Clinical Biochemistry, 44(5-6), 377-85. https://doi.org/10.1016/j.clinbiochem.2011.01.002
Chen HM, Lin CY, Wang V. Amyloid P Component as a Plasma Marker for Parkinson's Disease Identified By a Proteomic Approach. Clin Biochem. 2011;44(5-6):377-85. PubMed PMID: 21223953.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach. AU - Chen,Han-Min, AU - Lin,Ching-Yu, AU - Wang,Vinchi, Y1 - 2011/01/09/ PY - 2010/08/10/received PY - 2010/12/10/revised PY - 2011/01/01/accepted PY - 2011/1/13/entrez PY - 2011/1/13/pubmed PY - 2011/7/2/medline SP - 377 EP - 85 JF - Clinical biochemistry JO - Clin Biochem VL - 44 IS - 5-6 N2 - OBJECTIVES: Parkinson's disease (PD) ranks the second among the neurodegenerative disorders. Proteins involved in Parkinson's disease (PD) have been investigated but none as the diagnostic markers in blood. DESIGN AND METHODS: In this study, we applied a proteomic strategy, by utilizing two-dimensional electrophoresis and mass spectrometry, to analyze two sample pools of plasma from the healthy individuals and PD subjects. RESULTS: IgGκL and human serum amyloid P component (SAP) were found differentially expressed between these pools. SAP level increased by approximately 5-fold in PD samples, and the ELISA procedure revealed a significant (P<0.001) increase in SAP concentration (65.9 ± 18.7μg/mL) in the plasma of PD subjects (healthy individuals, 35.0 ± 12.5μg/mL), with sensitivity of 94.1% and specificity of 87.5%. CONCLUSION: Our results indicated a potential feasibility of plasma SAP as a marker to approach PD. SN - 1873-2933 UR - https://www.unboundmedicine.com/medline/citation/21223953/Amyloid_P_component_as_a_plasma_marker_for_Parkinson's_disease_identified_by_a_proteomic_approach_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(11)00020-8 DB - PRIME DP - Unbound Medicine ER -